TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14517707
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 200 mg
Study: 14517707
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 400 mg
Study: 11081780
Drug: Acute salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute salt loading with a 2 h infusion of isotonic saline
Study: 3936056
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (20 mg, 3-times daily)
Study: 3936056
Drug: Sustained-release glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release glyceryl trinitrate (6.4 mg, 3-times daily)
Study: 30463925
Drug: Amoxicillin-Clavulanate (Amox-Clav)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-Clavulanate (Amox-Clav)
Study: 24637411
Drug: EPA (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1800 mg/day) + statin (rosuvastatin)
Study: 11945144
Drug: Leukocyte alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte alpha n‐3 interferon (IFN‐L)
Study: 9718470
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg orally once daily for 3 days)
Study: 9718470
Drug: Clarithromycin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (7.5 mg/kg orally twice daily for 10 days)
Study: 2526959
Drug: Procaterol 0.02
Normalized name: procaterol 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol 0.02 mg
Study: 2526959
Drug: Salbutamol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.2 mg (control)
Study: 332505
Drug: practolol 100
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: practolol 100 mg
Study: 332505
Drug: practolol 400
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: practolol 400 mg
Study: 31070702
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEis)
Study: 22267465
Drug: darunavir/ritonavir (900/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (900/100 mg once daily)
Study: 22267465
Drug: raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: raltegravir (400 mg twice daily)
Study: 17224706
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (3-15 mg once daily, starting dose = 9 mg)
Study: 9733025
Drug: Antioxidant cocktail:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cocktail: 90 mg of Q10 and 13.5 mg of d‐alpha‐tocopheryl acetate daily (18 men)
Study: 8289481
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) 2 x 10 mg/m2 subcutaneously (s.c.) days 1‐14 plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) 2 x 150 micrograms protein/day s.c. given either following Ara C (days 15‐21) or simultaneously (days 8‐14) for 1‐5 cycles.
Study: 8289481
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LD-AraC) alone (not explicitly mentioned but referenced as ongoing evaluation).
Study: 1565294
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E supplements (800 mg dl‐alpha‐tocopherol acetate) for 30 days
Study: 755040
Drug: methysergide (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: methysergide (serotonin receptor blocker)
Study: 30247332
Drug: Laparoscopic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic rectal resection (Lap)
Study: 30247332
Drug: Open laparotomy
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open laparotomy and rectal resection (Open)
Study: 28086921
Drug: Web-based nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based nutrition education programme promoting vegetable intake (350 g per day, five small bowls)
Study: 19438416
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once-daily
Study: 19438416
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice-daily
Study: 19438416
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once-daily
Study: 19438416
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice-daily
Study: 19438416
Drug: Esomeprazole (once-daily)
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole (once-daily) vs Lansoprazole (once-daily)
Study: 19438416
Drug: Esomeprazole (twice-daily)
Normalized name: clindamycin
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole (twice-daily) vs Lansoprazole (twice-daily)
Study: 17307447
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of indicated secondary prevention medications (antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, lipid-lowering agents)
Study: 17307447
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of indicated secondary prevention medications
Study: 15362759
Drug: Perioperative music
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative music therapy with a key-lighting keyboard system (Group A)
Study: 7983994
Drug: Oral homoeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral homoeopathic immunotherapy to their principal allergen
Study: 24149925
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of soy flour (whole soy group)
Study: 24149925
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of low-fat milk powder + 63 mg of daidzein (daidzein group)
Study: 24149925
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of low-fat milk powder (placebo group)
Study: 18594318
Drug: Paclitaxel Poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel Poliglumex (PPX) 175 mg/m
Study: 18594318
Drug: Control (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single-agent vinorelbine or gemcitabine)
Study: 16403289
Drug: Cationic propyl
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cationic propyl gallate (C‐PG) at 100‐300 micromol/L
Study: 16403289
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at 200‐400 mg
Study: 12186195
Drug: Parenteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotics prescription
Study: 10822908
Drug: Carbohydrate solutions
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solutions (HFG, LFG, GLU, BAN, SUG)
Study: 10822908
Drug: Carbohydrate and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate and/or electrolytes in hydration solutions
Study: 1628294
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control agent
Study: 31294619
Drug: Diphencyprone immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphencyprone immunotherapy with intralesional meglumine antimoniate (MA)
Study: 25273912
Drug: maximum doses
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: maximum doses of ARB
Study: 22850442
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of rosuvastatin
Study: 20440152
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Quixil sealant and marginal quilting sutures (group 2)
Study: 18537963
Drug: Midazolam IV
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam IV (2 mg)
Study: 18537963
Drug: Midazolam oral
Normalized name: midazolam Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam oral (7.5 mg)
Study: 18537963
Drug: 1'-hydroxymidazolam oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1'-hydroxymidazolam oral
Study: 30628526
Drug: Core stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stabilization exercise therapy with bracing for 4 months
Study: 23813218
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml)
Study: 23813218
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA; target trough level of 80-100 ng/ml)
Study: 19203567
Drug: i.v. flumazenil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. flumazenil 0.005 mg/kg
Study: 18077945
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral pravastatin daily for 14 days
Study: 9640557
Drug: Regular AHA-blend
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular AHA-blend cream
Study: 9640557
Drug: Extra strength
Normalized name: APAP Extra Strength
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra strength AHA-blend cream
Study: 9640557
Drug: Control: non-AHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: non-AHA moisturizing lotion
Study: 9922479
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg per day (group II)
Study: 9922479
Drug: UDCA 150
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 150 mg per day (group I)
Study: 1833165
Drug: Nitrendipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20-40 mg/day) for 24 months
Study: 1833165
Drug: Captopril (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75-150 mg/day) for 24 months
Study: 6136841
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (200 mg every 6 h from 8 days before to 35 days after bone-marrow transplantation)
Study: 10793605
Drug: Saline 1
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1 ml
Study: 3527321
Drug: Oral ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ursodeoxycholic acid for 48 h before surgery
Study: 26596974
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg IV once daily
Study: 26596974
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg IV once daily
Study: 25001269
Drug: Trimetaphan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetaphan (4 mg/min IV, autonomic blocked day)
Study: 18377124
Drug: Family cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family cognitive‐behavioral therapy (FCBT)
Study: 10594562
Drug: benznidazole therapy
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: benznidazole therapy
Study: 1736755
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion (2 ml/kg of 50% vodka)
Study: 29397850
Drug: rhIL-11 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (1.5 mg/d)
Study: 22399248
Drug: Mosapride (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (15 mg/person/day) with PegIFN/RBV
Study: 19887462
Drug: Intensive protocol-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive protocol-based strategy involving bi-weekly visits for 16 weeks with medication adjustments as needed.
Study: 11999090
Drug: Diabetes (history
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes (history or fasting glucose > or =126 mg/dl)
Study: 11999090
Drug: Dyslipidemia (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyslipidemia (low HDL-cholesterol <40 mg/dl)
Study: 11999090
Drug: High total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: High total cholesterol (> or =200 mg/dl)
Study: 11999090
Drug: High LDL-cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High LDL-cholesterol (> or =130 mg/dl)
Study: 11999090
Drug: High triglycerides
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High triglycerides (> or =150 mg/dl)
Study: 183084
Drug: Cholestyramine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine therapy with a low cholesterol diet
Study: 183084
Drug: Out-patient follow-up
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient follow-up designed to reinforce patient motivation and dietary and drug adherence
Study: 31406538
Drug: Intranasal steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroids, antihistamines, leukotriene antagonists (Group 1)
Study: 26188833
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg combined with Simvastatin 10 mg (Vyto10)
Study: 26188833
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg combined with Simvastatin 20 mg (Vyto20)
Study: 26188833
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg alone (Simva20)
Study: 23328284
Drug: Lactulose treatment
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose treatment (n = 32)
Study: 23328284
Drug: Live binary
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live binary Bacillus subtilis treatment (n = 31)
Study: 23328284
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (n = 34)
Study: 18190369
Drug: Delayed feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed feeding (oral fluids 4 hours after surgery, diet at 24 hours)
Study: 15673875
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg IM
Study: 15673875
Drug: Morphine 12
Normalized name: morphine 120 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 12 mg IM
Study: 15673875
Drug: Morphine 6
Normalized name: apomorphine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 6 mg IM
Study: 15673875
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (Parecoxib sodium and morphine)
Study: 10589357
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclosporine (CSA) and methotrexate (MTX)
Study: 1940189
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC (1 tablet q.i.d., acid neutralizing capacity of 104 mEq/day)
Study: 6210686
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g iv dose of mezlocillin
Study: 6210686
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g iv dose of mezlocillin
Study: 6210686
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dose during haemodialysis (HD)
Study: 27995880
Drug: Generic dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Generic dasatinib (100 mg dose)
Study: 27995880
Drug: Reference dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reference dasatinib (100 mg dose)
Study: 20804269
Drug: Telephone-administered psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered psychotherapy for depression (16 weeks)
Study: 18978165
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg zinc gluconate/d
Study: 18978165
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc gluconate/d
Study: 18978165
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg zinc gluconate/d (placebo)
Study: 12558609
Drug: Racemic salbutamol
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic salbutamol inhaled three times during a 6-h period
Study: 12558609
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug treatment (control)
Study: 10053176
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 to 40 mg per day) with possible addition of enalapril (5 to 20 mg per day) or hydrochlorothiazide (12.5 to 25 mg per day) or both, titrated to reduce systolic blood pressure by at least 20 mm Hg and to less than 150 mm Hg.
Study: 30952386
Drug: Combined intra‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intra‐ and postoperative tranexamic acid (TXA) treatment
Study: 29394003
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch with replacement PIB adhesive (test)
Study: 29394003
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch with previously used PIB adhesive (reference)
Study: 22131101
Drug: Paquinimod (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paquinimod (4.5 mg/day and 6.0 mg/day)
Study: 22131101
Drug: Paquinimod (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paquinimod (up to 3.0 mg/day)
Study: 12067168
Drug: Combined antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibiotics (neomycin and metronidazole orally)
Study: 12067168
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (placebo)
Study: 10508004
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg moxifloxacin
Study: 10508004
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 400 mg moxifloxacin over 60 min
Study: 10508004
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of 400 mg moxifloxacin
Study: 31272285
Drug: Transfection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfection of miR‐145‐5p inhibitor
Study: 28846584
Drug: Preoperative interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative interventions (Expectation manipulation and Supportive therapy)
Study: 26782835
Drug: Intense hypertension
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense hypertension treatment
Study: 24421302
Drug: Alogliptin (ALO)
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin (ALO) 25 mg and Pioglitazone (PIO) 30 mg daily
Study: 24421302
Drug: Alogliptin (ALO)
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin (ALO) 25 mg daily monotherapy
Study: 17156824
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Study: 17156824
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose HT (2 mg 17 beta‐estradiol + 1 mg NETA)
Study: 12484051
Drug: PHAI (5-FU:
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHAI (5-FU: 500 mg/body/week for 50 cycles) plus oral UFT-E (400 mg/body/day for 24 months)
Study: 7926076
Drug: Dydrogesterone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (60 mg)
Study: 7926076
Drug: Dydrogesterone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (40 mg)
Study: 2684174
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of muroctasin for 6 days post-chemotherapy
Study: 2684174
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of muroctasin for 6 days post-chemotherapy
Study: 786689
Drug: Practolol (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (1600 mg/day)
Study: 786689
Drug: Chlorthalidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (100 mg 3 times weekly)
Study: 31157556
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing lozenges (three lozenges per day for two weeks)
Study: 31157556
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (three lozenges per day for two weeks)
Study: 28578646
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% with 100 mcg clonidine
Study: 28578646
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% with 4 mg dexamethasone and 100 mcg clonidine
Study: 28578646
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% with 4 mg dexamethasone